Johnson & Johnson faces push to force global ban on talc baby powder sales
The healthcare company Johnson & Johnson is facing an attempt to force a shareholder vote to halt its sales of talc-based baby powder across the world, including the UK, amid concerns over alleged links to cancer.
Johnson & Johnson (J&J) withdrew its talc-based baby powder from sale in the US and Canada in 2020. Sales of baby powder had dropped after US regulatorsdetected carcinogenic chrysotile fibres, a type of asbestos, in a sample.
The company is now facing more than 34,000 lawsuits including many from women who claim they used baby powder and later developed ovarian cancer.
The shareholder vote has been proposed by Tulipshare, a London-based investment platform which allows customers to pool their shares in order to meet the threshold to submit resolutions for shareholder votes. The proposal has been submitted to the US Securities and Exchange Committee (SEC) to consider if it is eligible ahead of J&J’s annual meeting, likely to be held in April.
Talc, the world’s softest mineral, is mined in several countries, with uses across industries as diverse as paper, plastics and pharmaceuticals. Talc’s astringent properties mean it is used to treat nappy rash and for other personal hygiene uses.
However, talc deposits can sometimes be contaminated with asbestos, a mineral that can cause cancer if its fibres enter the body. Corn starch can be used as a replacement.
J&J strongly denies that its baby powder is harmful and said it only pulled the product in North America after a slump in sales “fuelled by misinformation around the safety of the product”. A spokesperson pointed to a 2020 cohort study that found no statistically significant increased risk of ovarian cancer with talc use.
A spokesperson said: “We stand behind the
Read more on theguardian.com
